2024
Biologics for Psoriasis
Wride A, Chen G, Spaulding S, Tkachenko E, Cohen J. Biologics for Psoriasis. Dermatologic Clinics 2024, 42: 339-355. PMID: 38796266, DOI: 10.1016/j.det.2024.02.001.Peer-Reviewed Original ResearchConceptsIL-23IL-17ALong-term risk-benefit profileTNF-aLong-term adverse eventsIL-23 inhibitorsTumor necrosis factor-alphaP19 subunit of IL-23Risk-benefit profileSubunit of IL-23TNF-a inhibitorsTreatment of psoriasisNecrosis factor-alphaHigher Psoriasis AreaRates of short-termIL-12/23Psoriasis AreaIL-17FAdverse eventsIL-12IL-17Factor-alphaP19 subunitInjectable biologicsP40 subunit
2016
The effect of in-hospital acquired thrombocytopenia on the outcome of patients with acute coronary syndromes: A systematic review and meta-analysis
Oikonomou EK, Repanas TI, Papanastasiou C, Kokkinidis DG, Miligkos M, Feher A, Gupta D, Kampaktsis PN. The effect of in-hospital acquired thrombocytopenia on the outcome of patients with acute coronary syndromes: A systematic review and meta-analysis. Thrombosis Research 2016, 147: 64-71. PMID: 27689317, PMCID: PMC5515466, DOI: 10.1016/j.thromres.2016.09.026.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeNew onset thrombocytopeniaACS patientsCoronary syndromePlatelet countHigh riskSystematic reviewLong-term adverse eventsHospital heart failureSecondary cardiovascular endpointsMajor bleeding eventsOutcomes of patientsRecurrent myocardial infarctionAbnormal platelet countDevelopment of thrombocytopeniaShort-term mortalityLong-term outcomesNormal platelet countBleeding eventsHospital thrombocytopeniaLate deathsUnplanned revascularizationHospital stayAdverse eventsCardiovascular endpointsChina Patient-centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction: Study Design
Li J, Dreyer RP, Li X, Du X, Downing NS, Li L, Zhang HB, Feng F, Guan WC, Xu X, Li SX, Lin ZQ, Masoudi FA, Spertus JA, Krumholz HM, Jiang LX, Group T. China Patient-centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction: Study Design. Chinese Medical Journal 2016, 129: 72-80. PMID: 26712436, PMCID: PMC4797546, DOI: 10.4103/0366-6999.172596.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesAcute myocardial infarctionChina PatientMedical historyMyocardial infarctionPatient experienceLong-term adverse eventsRisk factor controlConsecutive AMI patientsAMI studyPatient's medical historyQuality of lifeNational Coordinating CentreQuality improvement activitiesHospital outcomesCardiac eventsPatient demographicsAdverse eventsMedical chartsHealthcare utilizationAMI patientsMedication adherenceProspective studyHospitalization eventsRisk factors
2005
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
D’Souza D, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57: 594-608. PMID: 15780846, DOI: 10.1016/j.biopsych.2004.12.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAkathisia, Drug-InducedArousalCognitionDose-Response Relationship, DrugDouble-Blind MethodDronabinolEndocrine SystemFemaleHumansInjections, IntravenousMaleMental RecallMiddle AgedMotor ActivityNeuropsychological TestsPerceptionPsychiatric Status Rating ScalesPsychotic DisordersPsychotropic DrugsSchizophreniaVerbal LearningConceptsSchizophrenia patientsAntipsychotic-treated schizophrenia patientsDelta-9-tetrahydrocannabinol effectsLong-term adverse eventsCognitive deficitsPlacebo-controlled studyDelta-9-THCTransient exacerbationAdverse eventsReceptor dysfunctionEndocrine effectsHealthy subjectsStudy participationPsychotic disordersPlasma prolactinSchizophrenia symptomsPatientsSchizophreniaCognitive effectsPerceptual alterationsDeficitsCannabisSubjectsAkathisiaExacerbation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply